A short-acting GHRH analog that produces physiological GH pulses when combined with a GHRP like Ipamorelin.
CJC-1295 without DAC (also known as Modified GRF 1-29 or Mod GRF 1-29) is a synthetic analog of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). The No DAC designation refers to the absence of a Drug Affinity Complex — a lysine-maleimide modification that, in the DAC version, allows the peptide to bind to albumin and dramatically extends its half-life. Without DAC, CJC-1295 has a half-life of approximately 30 minutes, closely mimicking the pulsatile nature of endogenous GHRH secretion. This physiological pulsatility is considered advantageous because it preserves the natural GH secretion pattern, reducing the risk of pituitary desensitization. It is almost universally combined with a GHRP such as Ipamorelin to achieve synergistic GH release through complementary receptor pathways.
* Benefits based on preclinical/animal research unless otherwise noted.
CJC-1295 No DAC binds to and activates GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland. GHRHR is a Gs protein-coupled receptor; its activation stimulates adenylyl cyclase, elevating intracellular cAMP, which activates protein kinase A (PKA) and ultimately drives GH synthesis and secretion. The short half-life ensures that pituitary stimulation occurs in discrete pulses rather than continuously, which is important because continuous GHRH stimulation leads to receptor downregulation and blunted GH response. When combined with Ipamorelin (a ghrelin receptor agonist), the two peptides act on different receptor systems — GHRHR and GHSR-1a respectively — producing a synergistic GH pulse that is 2–10 times greater than either agent alone. This combination also suppresses somatostatin (the endogenous GH inhibitor) through ghrelin receptor signaling, further amplifying the GH response.
Protocol Notes: Always combine with Ipamorelin for synergistic GH release. Administer on empty stomach. Bedtime dose is most important. Inject CJC-1295 No DAC and Ipamorelin simultaneously or within minutes of each other.
Add 2 mL bacteriostatic water to 2 mg vial → 1000 mcg/mL For 100 mcg dose: draw 0.1 mL (10 units on U-100 syringe)
When sourcing CJC-1295 No DAC for research purposes, the following quality benchmarks should be verified before use.
Lyophilized: refrigerate. Reconstituted: refrigerate and use within 30 days.
The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.
Moderate Evidence — Multiple animal studies and/or early human trials. Reasonable confidence in mechanism, but human data is limited.
Peptides commonly used alongside CJC-1295 No DAC for synergistic effects.
Gonadotropin
A naturally occurring gonadotropin that stimulates testosterone production and maintains testicular function during TRT.
Learn More: HCGIGF-1 Analog
A long-acting analog of IGF-1 with enhanced receptor binding and extended half-life for anabolic and recovery effects.
Learn More: IGF-1 LR3